CClinicalTrials.gg
Status unknownNCT05157737Updated Dec 15, 2021

Clinical Phenotype and Omics Study of KCNQ2-related Epilepsy

An observational study in KCNQ2-related Epilepsy, sponsored by Fudan University. Status unknown at 1 site in China. Open to participants aged Up to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-15.

Sponsored by Fudan University · Observational

The sponsor has not verified this record recently (last verified Dec 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
Up to 18 Years
Sex
All
01

Study summary

The aims of study on KCNQ2-related epilepsy: (1) establish phenotype database and sample database of KCNQ2-related epilepsy; (2) to establish genotype-phenotype association of KCNQ2-related epilepsy; (3) to study the brain network of KCNQ2-related epilepsy based on multi-modal brain image and EEG data; (4) to find prognostic biomarkers of KCNQ2-related epilepsy based on omics study.

Read the detailed description
  1. Participant recruitment: participants are recruited from Chinese KCNQ2-related epilepsy patients group (http://www.kcnq2.cn/). According to the clinical phenotype, the participants will be divided into benign familial neonatal seizures (BFNS) group and Developmental and epileptic encephalopathy (DEE) group.
  2. Genotype-phenotype association: electrophysiological detection of KCNQ2 mutation will be performed using patch clamp technique in an in vitro cell model. The association between phenotype (such as epileptic phenotype, developmental assessment and drug response) and genotype will be analyzed.
  3. Brain network analysis: participants who provide informed consent will be scaned by brain magnetic resonance imaging (MRI) or positron emission tomography-computed tomography (PET-CT) and monitored by the electroencephalogram (EEG). The Brain Network of KCNQ2-related epilepsy will be analyzed based on multi-modal brain image and EEG between BFNS and DEE group.
  4. Omics Study: after informed consent, blood, urine and feces samples of participants will be taken. The samples were tested for omics study including proteomics, metabolomics, transcriptomics, to analysis the difference of BFNS and DEE group.
02

Conditions studied

  • KCNQ2-related Epilepsy

Browse trials for

Keywords

  • KCNQ2-related epilepsy
  • Benign familial neonatal seizures
  • Developmental and epileptic encephalopathy
  • Genotype-phenotype association
  • Brain network
  • Omics study
03

In context

Epilepsy

1,805 studies on the registry are indexed under Epilepsy; 417 are open to participants now.

This study's planned enrollment of 200 is above the median of 102 across 521 observational studies indexed under Epilepsy.

Browse Epilepsy studies →

Lead sponsor

Fudan University is the lead sponsor of 1,270 studies on the registry; 623 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The patients of KCNQ2-related epilepsy who meet the clinical and genetic diagnosis criteria.

Inclusion criteria

  • KCNQ2 mutation was confirmed by WES, Panel and other gene tests;
  • Clinically diagnosed as epilepsy;
  • KCNQ2 mutation was identified as pathogenic or possibly pathogenic according to ACMG pathogenicity rating standard;
  • Age and gender are not limited;
  • No abnormal birth history;
  • Informed consent and willingness to follow up

Exclusion criteria

Exclusion Criteria:

  • Patients with KCNQ2 mutation without epilepsy;
  • Other possible pathogenic gene mutations except KCNQ2;
  • Large cross-gene deletions or duplications including KCNQ2;
  • Unable to participate in the study follow-up
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • BFNS group

    (1) Epileptic seizure in neonatal period; (2) Epileptic seizure duration is short, which under spontaneous control in 4\~6 months; (3) The patient was in normal state of feeding, physical examination and psychomotor development; (4) There were no signs of hypsarrhythmia or burst suppression in EEG.

    Other: Electrophysiological detection of KCNQ2 mutation · Other: Multi-modal brain image and EEG · Other: Omics testing

  • DEE group

    (1) Epileptic seizures occur within a week after birth and recur frequently; (2) Epilepsy is refractory; (3) Feeding difficulties, accompanied by moderate to severe mental retardation and psychomotor retardation; (4) The EEG showed hypsarrhythmia or burst suppression.

    Other: Electrophysiological detection of KCNQ2 mutation · Other: Multi-modal brain image and EEG · Other: Omics testing

Interventions

  • OtherElectrophysiological detection of KCNQ2 mutation

    Electrophysiological detection of KCNQ2 mutation performed using patch clamp technique in an in vitro cell model. Analyze the association between phenotype and genotype.

  • OtherMulti-modal brain image and EEG

    Multi-modal brain image include brain magnetic resonance imaging (MRI) or positron emission tomography-computed tomography (PET-CT). The electroencephalogram (EEG) incuding video electroencephalogram (VEEG) and sleep electroencephalogram (SEEG).

  • OtherOmics testing

    Omics testing include proteomics, metabolomics, transcriptomics.

06

What researchers measure

Primary outcomes

  1. Establish the phenotype database and genotype-phenotype association of KCNQ2-related Epilepsy

    Analysis of Clinical information of KCNQ2-related Epilepsy such as phenotype, genotype, brain image ,EEG, living quality and comorbidity.

    Time frame: 0-18 years old

  2. Study on the brain network of KCNQ2-related epilepsy

    Analysis of brain network of KCNQ2-related epilepsy based on multi-modal brain image and EEG

    Time frame: 0-18 years old

  3. Study on the omics testing of KCNQ2-related epilepsy

    Analysis of prognostic biomarker of KCNQ2-related epilepsy based on proteomics, metabolomics, transcriptomics.

    Time frame: 0-18 years old

07

Study locations

1 of 1 sites recruiting
  • Children's Hospital of Fudan University
    Shanghai, Shanghai 200232, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05157737
Lead sponsor
Fudan University
Responsible party
Yi Wang (Professer, Fudan University) — Principal investigator
First posted
Dec 15, 2021
Start date
Jan 1, 2021
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Dec 15, 2021

Study contacts

Yi Wang, Dr
Contact
yiwang@shmu.edu.cn
13564766228
Yi Wang, Dr
principal investigator · Children's Hospital of Fudan University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion